Insider Makes Significant Stock buy in Immune Design (IMDZ) Shares Extends the Trend of Last 90 Days

Monday, October 30, 2017 10:15 PM ET

Insider Makes Significant Stock buy in Immune Design (IMDZ) Shares Extends the Trend of Last 90 Days

One Immune Design insider — Column Group Lp, 10% Owner — today, acquired 2,681,000 shares having a market value of approximately $10,992,100, as disclosed in a form 4 document filed with the SEC. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been buys resulting in the purchase of 2,706,000 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net purchases of 5,387,000 shares and have averaged 1,795,667 shares per transaction over this time period.

Over the last 90 days, the number of insider buy/sell trades at Immune Design is higher than the 269-company peer group average. Bio Therapeutic Drugs peer group saw 329 buy/sell trades during this period for an average of 1.2 transactions per company. The number of shares per buy/sell trade for Immune Design insiders was also higher. Within the peer group there were 23,637,225 shares purchased and 12,315,044 shares sold with company insiders having bought 55,230 shares on average.

The data sourced in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.